生物技术公司Opus Genetics Inc近日宣布成功设立新的票据融资机制，通过该渠道可获得总额高达1.55亿美元的非稀释性资金支持。值得关注的是，该融资方案首期即提供3500万美元的即时资金注入。
此次融资安排采用票据融资模式，既保障了公司研发资金的持续供给，又有效避免了股权稀释对现有股东权益的影响。非稀释性融资的特性使公司在保持资本结构稳定的同时，能够灵活调配资源推进基因治疗领域的创新研究。
该融资机制将分阶段释放资金，后续款项的拨付将与公司达成特定研发里程碑挂钩。这种结构化设计既体现了投资方对Opus Genetics技术实力的认可，也为公司未来的科研进展提供了持续动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.